File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major

TitleEffect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major
Authors
KeywordsArterial function
Beta-thalassaemia major
Deferasirox
Issue Date2008
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJH
Citation
British Journal Of Haematology, 2008, v. 141 n. 5, p. 728-733 How to Cite?
AbstractDeferasirox (ICL670) has been shown to have rapid accessibility to intracellular labile iron. We tested the hypothesis that oral deferasirox improves arterial dysfunction in patients with beta-thalassaemia major. Nineteen thalassaemia patients, aged 23 ± 7 years, with normal left ventricular (LV) function were treated with deferasirox at 25-35 mg/kg/d for 12 months. LV function, brachial arterial flow-mediated dilation (FMD), carotid arterial stiffness, and serum ferritin levels were determined at baseline prior to initiation, after 6 months and after 12 months of therapy. The baseline cardiovascular indices were compared with those of 17 age-matched controls. Longitudinal changes in patients during the treatment period were also determined. Compared with controls, patients had similar echocardiographic indices of LV function (all P > 0.05), while their baseline brachial FMD was reduced (P < 0.001) and carotid stiffness increased (P = 0.019). An increase in FMD (P < 0.001) and a decrease in carotid stiffness (P = 0.007) were found at 6 and 12 months follow-up. The stiffness index correlated inversely with FMD (r = -0.42, P = 0.001). Although there was an increase in ferritin level at 12 months (3303 ± 1185 ng/ml vs. 2714 ± 780 ng/ml at baseline, P = 0.006), no significant correlation existed between ferritin level and FMD or carotid stiffness. In conclusion, deferasirox therapy in thalassaemia patients is associated with improved arterial function. © 2008 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/80045
ISSN
2015 Impact Factor: 5.401
2015 SCImago Journal Rankings: 2.313
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, YFen_HK
dc.contributor.authorChan, GCFen_HK
dc.contributor.authorHa, SYen_HK
dc.date.accessioned2010-09-06T08:01:44Z-
dc.date.available2010-09-06T08:01:44Z-
dc.date.issued2008en_HK
dc.identifier.citationBritish Journal Of Haematology, 2008, v. 141 n. 5, p. 728-733en_HK
dc.identifier.issn0007-1048en_HK
dc.identifier.urihttp://hdl.handle.net/10722/80045-
dc.description.abstractDeferasirox (ICL670) has been shown to have rapid accessibility to intracellular labile iron. We tested the hypothesis that oral deferasirox improves arterial dysfunction in patients with beta-thalassaemia major. Nineteen thalassaemia patients, aged 23 ± 7 years, with normal left ventricular (LV) function were treated with deferasirox at 25-35 mg/kg/d for 12 months. LV function, brachial arterial flow-mediated dilation (FMD), carotid arterial stiffness, and serum ferritin levels were determined at baseline prior to initiation, after 6 months and after 12 months of therapy. The baseline cardiovascular indices were compared with those of 17 age-matched controls. Longitudinal changes in patients during the treatment period were also determined. Compared with controls, patients had similar echocardiographic indices of LV function (all P > 0.05), while their baseline brachial FMD was reduced (P < 0.001) and carotid stiffness increased (P = 0.019). An increase in FMD (P < 0.001) and a decrease in carotid stiffness (P = 0.007) were found at 6 and 12 months follow-up. The stiffness index correlated inversely with FMD (r = -0.42, P = 0.001). Although there was an increase in ferritin level at 12 months (3303 ± 1185 ng/ml vs. 2714 ± 780 ng/ml at baseline, P = 0.006), no significant correlation existed between ferritin level and FMD or carotid stiffness. In conclusion, deferasirox therapy in thalassaemia patients is associated with improved arterial function. © 2008 The Authors.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJHen_HK
dc.relation.ispartofBritish Journal of Haematologyen_HK
dc.rightsBritish Journal of Haematology. Copyright © Blackwell Publishing Ltd.en_HK
dc.subjectArterial functionen_HK
dc.subjectBeta-thalassaemia majoren_HK
dc.subjectDeferasiroxen_HK
dc.titleEffect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia majoren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0007-1048&volume=141&spage=728&epage=733&date=2008&atitle=Effect+of+deferasirox+(ICL670)+on+arterial+function+in+patients+with+beta-thalassaemia+majoren_HK
dc.identifier.emailCheung, YF:xfcheung@hku.hken_HK
dc.identifier.emailChan, GCF:gcfchan@hkucc.hku.hken_HK
dc.identifier.authorityCheung, YF=rp00382en_HK
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1365-2141.2008.07092.xen_HK
dc.identifier.pmid18318756-
dc.identifier.scopuseid_2-s2.0-43449089514en_HK
dc.identifier.hkuros142313en_HK
dc.identifier.volume141en_HK
dc.identifier.issue5en_HK
dc.identifier.spage728en_HK
dc.identifier.epage733en_HK
dc.identifier.isiWOS:000255643700020-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCheung, YF=7202111067en_HK
dc.identifier.scopusauthoridChan, GCF=16160154400en_HK
dc.identifier.scopusauthoridHa, SY=7202501115en_HK
dc.identifier.citeulike2798184-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats